PubHawk
BJU Int December 2016 PMID 27415448

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Athene Lane, Chris Metcalfe, Grace J Young, Tim J Peters, Jane Blazeby, Kerry N L Avery, Daniel Dedman, Liz Down, Malcolm D Mason, David E Neal, Freddie C Hamdy, Jenny L Donovan

Full text PDF Download social card

Mentions

5
Peak: 2 in Aug 2022
across 3 sources since Nov 2016

Extended reach

34,854
potential audience

Total likes

2

Video views

297

Mentions per month

Nov 2016 – Aug 2022

Where it's discussed

  • X / Twitter2 posts
  • Blogs2 articles
  • YouTube1 videos

AI synopsis

What people are saying

The collective discussions demonstrate strong support and keen interest in patient-reported outcomes, with examples like mentions of 'helping us walk in the patient's shoes' and calls for prioritizing such metrics as primary endpoints. The tone suggests a recognition of the importance and potential impact of the research; debates about endpoints and the emphasis on patient-centered care reflect both engagement and impact.

AgreementModerate agreement

Most discussions express support for the importance of patient-reported outcomes in prostate cancer treatment evaluation, emphasizing thorough analysis and consideration of patient perspectives.

InterestHigh interest

The topic of quality of life and patient perspectives in prostate cancer research generates high interest, as evidenced by detailed comments and multiple mentions of methods and implications.

EngagementModerate engagement

Participants engage actively by referencing specific endpoints, methodologies, and suggesting improvements, indicating a moderate to deep level of discourse.

ImpactModerate impact

The discussions highlight the significance of incorporating patient-reported outcomes for treatment assessment, and some emphasize potential changes in clinical practice and research priorities.

Abstract in brief

  • The study presents baseline patient-reported outcomes (PROMs) for men with localized prostate cancer in the ProtecT trial, comparing different treatment options like active monitoring, surgery, and radiotherapy, and includes assessments of urinary, bowel, sexual function, and overall quality of life.
  • Data was collected from 1643 men aged 50-69 across nine UK cities before treatment, using validated questionnaires such as EPIC, ICIQ, ICSmaleSF, HADS, SF12, and EQ5D, and analyzed based on treatment groups, age, and test dates.
  • Results showed low usage of pads, frequent urinary issues like nocturia, rare bowel symptoms, and about one-third of men reporting erectile dysfunction; depression was uncommon, but 20% experienced moderate to large problems with sexual function, highlighting the impact of prostate cancer and its treatments on quality of life.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Michael Baum
@MichaelBaum11 · X

@paulpharoah @1987Andrewk @pash22 @axelheitmueller @susan_bewley @sib313 @MrJohnMBennett @mancunianmedic @mdlhenning @invadingpirate @vicky_dmail @ginakolata @hormone_doc @NICEComms @NicholasZaorsky @NHSEngland @icer_review @CADTH_ACMTS @drjohnm @adamcifu @AndrewFoy82 @VPrasadMDMPH @OBR_UK @drtimwilson @joemcmanners I agree that all-cause mortality should be the primary endpoint, in addition, helping us "walk in the patient's shoes" should be considered as a secondary endpoint. In the ProtecT trial, we measured patient reported outcomes (PROMS) https://t.co/3VkhAyJmcU

Aug 22, 2022 · 2 likes · 1 share · 2,251 followers View post →
Ash Paul
@pash22 · X

RT @MichaelBaum11: @paulpharoah @1987Andrewk @pash22 @axelheitmueller @susan_bewley @sib313 @MrJohnMBennett @mancunianmedic @mdlhenning @in…

Aug 22, 2022 · 1 share · 32,302 followers View post →

All mentions

Ash Paul
@pash22 · X

RT @MichaelBaum11: @paulpharoah @1987Andrewk @pash22 @axelheitmueller @susan_bewley @sib313 @MrJohnMBennett @mancunianmedic @mdlhenning @in…

Aug 22, 2022 · 1 share · 32,302 followers View post →
Michael Baum
@MichaelBaum11 · X

@paulpharoah @1987Andrewk @pash22 @axelheitmueller @susan_bewley @sib313 @MrJohnMBennett @mancunianmedic @mdlhenning @invadingpirate @vicky_dmail @ginakolata @hormone_doc @NICEComms @NicholasZaorsky @NHSEngland @icer_review @CADTH_ACMTS @drjohnm @adamcifu @AndrewFoy82 @VPrasadMDMPH @OBR_UK @drtimwilson @joemcmanners I agree that all-cause mortality should be the primary endpoint, in addition, helping us "walk in the patient's shoes" should be considered as a secondary endpoint. In the ProtecT trial, we measured patient reported outcomes (PROMS) https://t.co/3VkhAyJmcU

Aug 22, 2022 · 2 likes · 1 share · 2,251 followers View post →